Drug maker Boehringer Ingelheim (BI) sued the federal government to block Medicare price negotiations shortly before the Department of Health [...] …
Articles by : William Newton, Associate Editor/Senior Writer
The Department of Health and Human Services (HHS) today announced the first 10 prescription drugs eligible for Medicare price negotiations [...] …
Please Login or Become a Paid Subscriber to View this Content
If you are already a
Drugmaker AstraZeneca sued the federal government to block Medicare drug price negotiations on Friday, just days before the government announced [...] …
Please Login or Become a Paid Subscriber to View this Content
If you are already a
A health center challenging the government’s 340B program patient definition in a federal district court recently asked a federal judge [...] …
Please Login or Become a Paid Subscriber to View this Content
If you are already a
A federal appeals court has scheduled oral arguments for September in a case challenging Arkansas’ protections for 340B providers’ contract [...] …
Please Login or Become a Paid Subscriber to View this Content
If you are already a
Two drug manufacturers are sending 340B covered entities refunds for overcharges totaling $100 or more, according to public filings posted [...] …
Please Login or Become a Paid Subscriber to View this Content
If you are already a
Drug manufacturer AstraZeneca, one of the first companies to place restrictions on 340B discounts in the contract pharmacy setting, has [...] …
Please Login or Become a Paid Subscriber to View this Content
If you are already a
The 340B drug pricing program does not improve inpatient care quality for underserved patients, a recent government-funded analysis concluded. A [...] …
Please Login or Become a Paid Subscriber to View this Content
If you are already a
While two drug manufacturers have recently relaxed or suspended their 340B contract pharmacy restrictions as a result of state laws [...] …
Please Login or Become a Paid Subscriber to View this Content
If you are already a
The U.S. Government Accountability Office late last month restated its controversial recommendation that Congress take actions to reduce incentives for [...] …
